Novo Nordisk (Italy)

Recent papers from Novo Nordisk (Italy)

1. Somapacitan Treatment in Children and Adolescents Born SGA: Two-Year Efficacy and Preference Over Daily GHThe Journal of Clinical Endocrinology & Metabolism · 2026
2. Temporal trends and clinical predictors of GLP-1 receptor agonist and SGLT2 inhibitor use after myocardial infarction among patients with type 2 diabetesEuropean Heart Journal · 2026
3. Epidemiology and clinical characteristics of patients eligible for novel cardiovascular preventive therapies: a real-world analysis of data from general practice doctors in Italian populationEuropean Heart Journal · 2026
4. Association between elevated C-reactive protein and mortality, healthcare resource utilization and costs in patients with atherosclerotic cardiovascular disease and/or chronic kidney diseaseEuropean Heart Journal Open · 2026
5. Weight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trialsEClinicalMedicine · 2026
6. Assessment of changes in quality of life after thyroid surgery in older adults. A prospective studyFrontiers in Endocrinology · 2026
7. Burden of Systemic Inflammation Among Individuals with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease in Northern ChinaCardiology and Therapy · 2026
8. A cross-regional initiative for improving type 2 diabetes mellitus care quality measurement in Spain – The Diabetes Lighthouse projectPrimary care diabetes · 2026
9. Projecting the Long‐Term Cost‐Effectiveness of Once‐Weekly Insulin Icodec Versus Once‐Daily Basal Insulin Analogs in Italy Using the Prime T2D ModelDiabetes Obesity and Metabolism · 2026
10. User demographics and real-world use of the digital diabetes companion app dibi: a retrospective analysisFrontiers in Digital Health · 2026
11. Oral semaglutide and CV benefits in the SOUL trial: how do baseline or changes in HbA1c and BMI affect clinical outcomes?The Journal of Clinical Endocrinology & Metabolism · 2026
12. Tipping the balance: impact of class imbalance correction on the performance of clinical risk prediction modelsJournal of the American Medical Informatics Association · 2026
13. Modelling the Clinical and Complication‐Related Economic Burden of Therapeutic Inertia in People With Type 2 Diabetes in ChinaDiabetes Obesity and Metabolism · 2026
14. Determinants of Clinically Significant Weight Loss Among People with Obesity: The Roles of Healthcare Engagement, Motivation, and ComorbiditiesObesities · 2026
15. Order Effects and Teacher Labor Supply: A Nationwide RCT in EcuadorAmerican Economic Journal Applied Economics · 2026
16. Knowledge, attitudes, and perceptions of community pharmacists regarding the care of children with autism spectrum disorder: a cross-sectional study in the United Arab EmiratesBMC Public Health · 2026
17. Awareness and perceptions of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: The SPARK-CVD China surveyAtherosclerosis Plus · 2026
18. The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary CareAlimentary Pharmacology & Therapeutics · 2026
19. How Filipinos View ObesityJournal of the ASEAN Federation of Endocrine Societies · 2026
20. Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian studyDiabetes Research and Clinical Practice · 2026